Table 4.

Increased levels of CK18 in patient serum during treatment using different agents

TreatmentIncreased levels of CK18 during therapy (%)
Caspase cleaved*Total*
Docetaxel (breast)19.8 (P = 0.0089)16.5 (NS)
Docetaxel (prostate)18.7 (P < 0.0001)21.4 (P < 0.0002)
Vinorelbine (prostate)7.2 (P < 0.001)6.7 (P < 0.011)
Estramustine (prostate)−1 (NS)8.2 (P < 0.0001)
CEF (breast)§12.9 (P < 0.00001)32.7 (P < 0.00001)
  • * Increased median levels of CK18-Asp396 and total CK18 (measured by the M30-Apoptosense and M65 ELISA assays).

  • Increase over pretherapy levels at 72 h.

  • Increase over pretherapy levels 48 h (prostate data are from ref. 13).

  • § Increase over pretherapy levels at 24 h.